|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Peptide sequence around phosphorylation site of threonine 183 (M-M-T(p)-P-Y) derived from Human SAPK/JNK.|
|Storage buffer||PBS, pH 7.4, with 50% glycerol|
|Contains||0.02% sodium azide|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:100|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control for Western blot is 293 cells; suggested positive control for IHC is human breast carcinoma.
C-Jun N-terminal Kinase (JNK) is also known as Mitogen-activated protein kinase (MAPK8). It belongs to the MAPK superfamily of stress-activated protein kinases. MAPKs are Serine-threonine protein kinases that are activated in response to a variety of extracellular stimuli, and mediate signal transduction from the cell surface to the nucleus. JNK is involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. JNK pathways are activated by stress and inflammatory signals. JNK is expressed as ten different isoforms due to differential mRNA splicing. The predominant forms are JNK1 and JNK2.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.